The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion

Diagnostic Cytopathology

Volumn 32, Issue 3, 2005, Pages 160-166

  Dejmek, Annika ^a   Hjerpe, Anders ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ACA; Effusion; Hyaluronan; Immunocytochemistry; Mesothelioma

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPITHELIAL MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BEREP4; MONOCLONAL ANTIBODY HBME 1; MONOCLONAL ANTIBODY SIALYL TN; THROMBOMODULIN; UNCLASSIFIED DRUG; VIMENTIN;

ADENOCARCINOMA; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MESOTHELIOMA; PLEURA EFFUSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYALURONIC ACID; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PLEURAL EFFUSION, MALIGNANT; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 13844265913     PISSN: 87551039     EISSN: None     Source Type: Journal    
DOI: 10.1002/dc.20202     Document Type: Article

References (32)

1. La Vecchia C, Decarli A, Peto J, Levi F, Tomei F, Negri E. An age, period, and cohort analysis of pleural cancer mortility in Europe. Eur J Cancer Prev 2000;9:179-184.
2. Kjaergaard J, Andersson M. Incidence rates of malignant mesothelioma in Denmark and predicted future number of cases among men. Scand J Work Environ Health 2000;26:112-117.
3. Kho-Duffin J, Tao L-C, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the epithelial noncohesive cell type. Diagn Cytopathol 1999;20:57-62.
4. Fetsch PA, Abati A. Immunocytochemistry in Effusion Cytology. A contemporary Review. Cancer Cytopathol 2001;93:293-308.
5. Ordonez NG. The immunohistochemical diagnosis of epithelial mesothelioma. Hum Pathol 1999;30313-323
6. Carella R, Deleonardi G. D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
7. Cangi MG, Pecciarini L, Doglioni C. The role of immunocytochemistry in the differential diagnosis of serous effusions. Adv Clin Path 2000;4:183-185.
8. Lozano MD, Panizo A, Toledo GR, Sola JJ. Pardo-Mindan J. Immunocytochemistry in the differential diagnosis of serous effusions: a comparative evaluation of eight monoclonal antibodies in Papanicolaou stained smears. Cancer 2001;93:68-72.
9. Queiroz C, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cytol 2002;45:18-22.
10. Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-209.
11. Ordonez NG. Immunohistochemical diagnosis of epithelial mesotheliomas: a critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
12. Moran CA, Wick MR, Suster S. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Semin Diagn Pathol 2000; 114:203-209.
13. Leong A S-Y, Suthipingtawong C, Vinyuvat S. Immunostaining of cytologic preparations: a review of technical problems. Appl Immunohistochem 1999;7:214-220.
14. Laurent UBG, Tengbladh A. Determination of hyaluronate in biological samples by a specific radio assay. Acta Biochem 1980;109:386-395.
15. Hillerdal G, Lindquist U, Engstrom-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer 1991;7:2410-2414.
16. Nurminen M, Dejmek A, Mårtensson G Thylen A, Hjerpe A. Clinical utility of liquid-chromatografic analysis of effusions for hyaluronanate content. Clin Chem 1994;40:777-780.
17. Dejmek A, Hjerpe A. Reactivity of six antibodies in effusions of mesothelioma, adenocarcinoma, and mesotheliosis:stepwisw logistic regression analysis. Cytopathology 2000;11:8-17.
18. Stevens MW, Leong AS, Fazzalari NL, Dowling KD, Henderson DW. Cytopathology of malignant mesothelioma: a stepwise logistic regression analysis. Diagn Cytopathol 1992;8:333-341.
19. Ordonez NG. The immunohistochemical diagnosis of mesothelioma: differentiation of mesothelioma and lung adenocarcinoma. Am J Surg Pathol 1989;13:276-296.
20. Dejmek A, Hjerpe A. Immunohistochemical reactivity in mesothelioma and adenocarcinoma: a stepwise logistic regression analysis. APMIS 1994;102:255-264.
21. Bailey ME, Brown RW, Mody DR, Cagle P, Ramzy I. BerEp4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72,3, and Leu-M1. Acta Cytol 1996;40:1212-1216.
22. Brockstedt A, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;17:178-183.
23. Ascoli V, Carnovale-Scalzo C, Taccogna S, Nardi F. Utility of HBME-1 immunostaining in serous effusions. Cytopathology 1997;8: 328-325.
24. Abata A, Hijazi YM. Utility of the antibodies CA 19-9. HBME-1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology. Cancer Cytopathol 1998;84:101-108.
25. Oates J, Edwards C. HBME-1, MOC-31, WT1, and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
26. Cury PM, Butcher DN, Fisher C, Corrin B, Nicholson AG. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura. Mod Pathol 2000;13:107-112.
27. Kitazume H, Kitamura K, Mukai K, et al. Cytologic diferential analysis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer (Cancer Cytopathol) 2000;90:55-60.
28. Imai J, Ghazizadeh M, Naito Z, Asano G. immunohistochemical expression of T, Tn, and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res 2001;21:1327-1334.
29. Kim GE, Bae HI, Park Hu et al. Aberrant expression of MUC5AC gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology 2002;123:1052-1060.
30. Pomjanski N, Motherby H, Buggstegge B, Knops K, Rohn BL, Bocking A. Early diagnosis of mesothelioma in serous effusions using AgNOR analysis. Anal Quant Cytol Histol 2001;23:151-160.
31. Motherby M, Marcy T, Hecker M. et al. Static DNA cytometry as a diagnostic aid in effusion cytology: 1. DNA aneuploidy for identification and differentiation of primary and secondary tumors of the serous membranes. Anal Quant Cytol Histol 1998;20:153-161.
32. Leong AS-Y, Parkinson R, Milios J. Thick cell membranes revealed by immunocytochemical staining: a clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990;6:9-13.